A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas trans
- 浏览1
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文